News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Antitope and Cantab Pharmaceuticals PLC (XNVA) Enter into a Research Agreement


3/23/2010 2:30:50 PM

23rd March 2010 - Antitope Ltd. (UK) today announced a research agreement with Cantab Biopharmaceuticals Ltd (Cambridge, UK) for the development of a biosuperior protein therapeutic in the area of haematology. As part of the agreement, Antitope will apply its proprietary technologies towards the generation of a high yielding mammalian cell line for manufacture of the therapeutic.

Dr Matthew Baker, Chief Scientific Officer and co-founder of Antitope commented, "We are very pleased to work with Cantab Biopharmaceuticals to assist in the development of their protein therapeutic. The partnership combines Antitope's core technologies for therapeutic proteins and the generation of high-yielding manufacturing cell lines with Cantab’s extensive experience in biopharmaceutical discovery, process development and GMP manufacturing."

Dr Jim Mills, CEO of Cantab Biopharmaceuticals commented, “with Antitope’s experience in molecular biology and manufacturing cell line production they are an ideal partner for us. I look forward to working closely with them as we move forward into realising our first product program within biosuperiors.”

About Antitope

Antitope Ltd. is a Cambridge UK-based biotechnology company specialising in immunogenicity testing, engineering of therapeutic antibodies/proteins to reduce immunogenicity and generation of manufacturing cell lines. Antitope's proprietary EpiScreenTM technology uses human T cells to measure the immunogenicity potential of biopharmaceuticals. Antitope's Composite Human AntibodyTM and Composite ProteinTM technologies deliver novel therapeutic antibodies and proteins with very low immunogenicity potential through the avoidance of T cell epitopes. Antitope’s expression technologies use its proprietary vector system for enhanced expression of biologics from mammalian cells. Antitope is a privately-held company and has established multiple commercial relationships with leading biotechnology and pharmaceutical companies. For further information on Antitope visit www.antitope.co.uk.

For further information contact:

Dr Neil Butt

Business Development Director, Antitope Ltd.

Tel: +44 (0)1223 496190

About Cantab Biopharmaceuticals

Cantab Biopharmaceuticals Ltd (CBL) is a drug development company focused on the development of "biosuperior" products. Cantab is based in Cambridge, UK at the heart of the largest biotech cluster in Europe. The company uses its extensive experience in biopharmaceutical discovery, process development and GMP manufacturing to expedite the development of biosuperiors from inception through clinical development. The strategy of the company is to add value to previously marketed, off-patent, biologics by applying cutting-edge technologies that address sub-optimal characteristics of the marketed product. Particular areas of drug characteristics that Cantab seek to improve upon are product presentation and stability, pharmacokinetics, pharmacodynamics, immunogenicity and drug delivery.

For further information, please visit www.cantabbio.com

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES